Skip to main content

CORRECTION article

Front. Oncol., 12 December 2023
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1347301

Corrigendum: The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy

This article is a correction to:

  1. The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy

    1. Read original article
Xiao-Han ZhaoXiao-Han Zhao1Wen-Bin Shen*Wen-Bin Shen1*Duo WangDuo Wang2He-Song WangHe-Song Wang1Chun-Yang SongChun-Yang Song1Wen-Zhao DengWen-Zhao Deng1
  • 1Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
  • 2Hebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, College of Life Sciences, Hebei Normal University, Shijiazhuang, China

A Corrigendum on
The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy

By Zhao X-H, Shen W-B, Wang D, Wang H-S, Song C-Y and Deng W-Z (2023) Front. Oncol. 13:1167625. doi: 10.3389/fonc.2023.1167625

Incorrect Affiliation

In the published article, there was an error in affiliation 1. The previous affiliation stated “Department of Radiation Oncology, the Forth Hospital of Hebei Medical University, Shijiazhuang, China,”. The corrected affiliation is: “Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China,”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: esophageal squamous cell carcinoma, second-line treatment, immune checkpoint inhibitors, controlling nutritional status, systemic inflammation score, prognosis

Citation: Zhao X-H, Shen W-B, Wang D, Wang H-S, Song C-Y and Deng W-Z (2023) Corrigendum: The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy. Front. Oncol. 13:1347301. doi: 10.3389/fonc.2023.1347301

Received: 30 November 2023; Accepted: 01 December 2023;
Published: 12 December 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Zhao, Shen, Wang, Wang, Song and Deng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wen-Bin Shen, wbshen1979@sina.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.